Manufacturing

Articles

The 135,000 square foot facility will be constructed over 18 months and is expected to be operational in 2021.

Audentes to Invest $109 Million into Gene Therapy Manufacturing Facility

Agnes Shanley is senior editor of Pharmaceutical Technology.

New funding brings competitors, and a leading healthcare products distributor, into the standardization effort.


Novartis, Kite, and Cardinal Health Invest in Cell and Gene Therapy Infrastructure

The new facility includes six classified environment rooms with space to expand.

Hitachi Chemical Opens New Cell and Gene Therapy Manufacturing Facility

Alberto Santagostino is senior vice-president and head of cell and gene technologies at Lonza Pharma and Biotech. 

Contract partners must help innovators, especially smaller and virtual companies, consider manufacturability as early as possible in development. This requires focusing on technical and operational performance, as well as cost. 

Using the ‘Cubic Effect’ to Drive Cell and Gene Therapy Commercialization

Vein-to-vein programs are focusing on data access and traceability. 

Managing Risk for Cell and Gene Therapy Logistics

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

As cell and gene therapies become more prominent, industry is seeking the expertise and capabilities of outsourcing partners to ensure success.

Sourcing Success in Cell and Gene Therapy Development

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

The need for manufacturing speed inspires contract manufacturers to explore advanced processing technologies.

More Capacity and Technology Translate to More Options

The new facility, to be operated under the newly formed CDMO, The Center for Breakthrough Medicines, will be located in King of Prussia, PA, and will increase manufacturing capacity for cell and gene therapies.

The Discovery Labs, Deerfield Management Create New CDMO and Invest $1.1 Billion in New Cell and Gene Therapy Facility

The new course is directed at analyzing the skills gap in the manufacture of cell and gene therapies as they progress toward manufacturing at scale.



CGT Catapult Partners with the University of Hertfordshire for Cell and Gene Therapy Course

The new company will work to provide the manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies through individual company products and expertise.

Manufacturing, Gene Therapies